The antibody therapeutics industry is growing at an incredible pace. From early monoclonal therapeutic antibodies to modern bispecific and multispecific antibodies, single domain antibodies (VHHs), ...

In the rapidly evolving field of antibody drug discovery, the ability to efficiently characterize and screen antibodies and antibody drug conjugates (ADCs) is crucial for developing effective ...

Monoclonal antibodies (mAbs) are one of the most successful therapeutic drug classes, generating lucrative sales for the pharmaceutical industry. In 2016, more than 20 therapeutic antibodies gained ...

insights from industryMohammed AkhlaqHead of AutomationLabGenius Therapeutics In this interview, News Medical speaks with Mohammed Akhlaq at LabGenius Therapeutics about how automation and machine ...

Carterra® Inc., the world leader in high-throughput antibody screening and characterization, announced today that they have opened a Customer Experience Center (CEC) and office in Munich, Germany.

Antibody discovery programs rely on high-throughput technologies to quickly identify candidates with therapeutic potential. Evaluating antibodies for the desired therapeutic mechanism of action is an ...

High throughput (HT) gene-to-antibody manufacturing is the most economical choice for small-scale recombinant antibodies. Small-scale projects can be finished in as little as 10 business days with the ...

Larry Sklar (left) is a Distinguished Professor Emeritus at the University of New Mexico (UNM; NM, USA) whose interest in flow cytometry as a tool for drug discovery led to the development of ...

For decades, antibodies have been one of the crown jewels of modern medicine—powerful molecules that can neutralize viruses, tame autoimmune diseases, and revolutionize cancer care. Yet despite their ...

The discovery and optimization of antibodies, whether through traditional methods or with the assistance of artificial intelligence, necessitates rapid and reliable data generation. Here we introduce ...